Last reviewed · How we verify
TP-434
At a glance
| Generic name | TP-434 |
|---|---|
| Also known as | Eravacycline |
| Sponsor | Tetraphase Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Therapeutic Options for CRAB (PHASE4)
- The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections
- A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI) (PHASE2)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients
- A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia (PHASE2)
- Eravacycline Combination Therapy for MRAB
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-434 CI brief — competitive landscape report
- TP-434 updates RSS · CI watch RSS
- Tetraphase Pharmaceuticals, Inc portfolio CI